Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates.

Published online

Journal Article

The detrimental effects of donor-directed antibodies in sensitized transplant patients remain a difficult immunologic barrier to successful organ transplantation. Antibody removal is often followed by rebound. Proteasome inhibitors (PIs) deplete antibody-producing plasma cells (PCs) but have shown marginal benefit for desensitization. In an allosensitized nonhuman primate (NHP) model, we observed increased germinal center (GC) formation after PI monotherapy, suggesting a compensatory PC repopulation mediated via GC activation. Here we show that costimulation blockade (CoB) targets GC follicular helper T (Tfh) cells in allosensitized NHPs. Combined PI and CoB significantly reduces bone marrow PCs (CD19+CD20-CD38+), Tfh cells (CD4+ICOS+PD-1hi), and GC B cells (BCL-6+CD20+); controls the homeostatic GC response to PC depletion; and sustains alloantibody decline. Importantly, dual PC and CoB therapy prolongs rejection-free graft survival in major histocompatibility complex incompatible kidney transplantation without alloantibody rebound. Our study illustrates a translatable desensitization method and provides mechanistic insight into maintenance of alloantibody sensitization.

Full Text

Duke Authors

Cited Authors

  • Kwun, J; Burghuber, C; Manook, M; Ezekian, B; Park, J; Yoon, J; Yi, JS; Iwakoshi, N; Gibby, A; Hong, JJ; Farris, AB; Kirk, AD; Knechtle, SJ

Published Date

  • November 14, 2017

Published In

Volume / Issue

  • 1 / 24

Start / End Page

  • 2115 - 2119

PubMed ID

  • 29296858

Pubmed Central ID

  • 29296858

International Standard Serial Number (ISSN)

  • 2473-9529

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2017010991

Language

  • eng

Conference Location

  • United States